1050. http://curareg.uroweb.org/Posters Paris2012/1050.%20Maurizio%20Brausi/Poster% 20-%201050.pdf11. Martinez-Pineiro JA, Flores N, Isorna S, et al. for CUETO (Club Urologico Espanol de Tratamiento Oncologico). Long-term follow-up of a randomized prospective trial comparing a standard 81 mg dose of intravesical bacille Calmette-Guérin with a reduced dose of 27 mg in superficial bladder can...

The influence of mineral oil content on the antitumor activity of emulsified Bacillus Calmette-Guérin cell walls (CW) was studied in mice each with an established transplant of a syngeneic fibrosarcoma. Animals received intratumoral injections of CW (0.02 to 0.6 mg/mouse) emulsified in 1 to 9% oil. The number of animals in which tumor regressed completely depended on the concentration of oil in...

Intravesical immunotherapy with attenuated strains of Mycobacterium bovis is a widely used therapeutic option in patients with non-muscle-invasive transitional cell carcinoma of the bladder. A rare complication of intravesical therapy with the Bacillus Calmette-Guérin vaccine is granulomatous prostatitis, which due to increasing levels of prostate-specific antigen and abnormalities found in tra...

Aim: This review is written to describe the role of immunotherapy in cancer treatment. Annually, 13,000 deaths result from bladder cancer. Since the first report of intravesical use of BCG in 1976, investigators try to understand the working mechanism of BCG as an antitumour modality. Arbitrarily, BCG therapy consists of a single course of six weekly intravesical instillations. Bacillus Calmett...

1. Mungan NA, Witjes JA. Bacille Calmette-Guérin in superficial transitional cell carcinoma. Br J Urol. 1998;82:213-223. 2. Schamhart DHJ, de Boer EC, de Reijke TM, Kurth KH. Urinary cytokines reflecting the immunological response in the urinary bladder to biological response modifiers: their practical use. Eur Urol. 2000;37(suppl 3):16-23. 3. Romani L, Puccetti P, Bistoni F. Interleukin-12 in ...

Intravesical instillation of Bacillus Calmette-Guérin is currently used as adjuvant therapy for superficial, non-muscle invasive bladder cancer (NMIBC). However, nearly 40% of patients with NMIBC will fail Bacillus Calmette-Guérin therapy. In an attempt to investigate the feasibility of using insect baculovirus-based vectors for bladder cancer therapy, we observed that intravesical instillation...

1. Mungan NA, Witjes JA. Bacille Calmette-Guérin in superficial transitional cell carcinoma. Br J Urol. 1998;82:213-223. 2. Schamhart DHJ, de Boer EC, de Reijke TM, Kurth KH. Urinary cytokines reflecting the immunological response in the urinary bladder to biological response modifiers: their practical use. Eur Urol. 2000;37(suppl 3):16-23. 3. Romani L, Puccetti P, Bistoni F. Interleukin-12 in ...

We read with great interest the article by Guérin and colleagues, in the November 2010 issue of RESPIRATORY CARE,1 describing analysis of acid-base disorders with the Stewart method versus the conventional approach in patients with chronic respiratory failure in stable or unstable respiratory condition. Unfortunately, we find several aspects of the analysis to be rather misleading. First, accor...

Non-muscle-invasive bladder cancer is a frequent and heterogeneous disease with varying oncologic outcomes. The main goal in treating is to prevent recurrences and progression to muscle-invasive disease. Developments to improve the quality of transurethral resection of the bladder tumor and new chemotherapeutic options, including two device-assisted therapies, are being discussed. A problem is ...

Recibido: 08/08/2009 Aceptado: 02/10/2009 Introduction Short title: Bacillus Calmette-Guérin disease after intravesical instillation Two exemplary case reports of respiratory granulomatous infection caused by bacillus of Calmette-Guérin (BCG) in patients who were repeatedly treated with local, intravesical adjuvant BCG therapy for a relapsing transitional bladder carcinoma, are outlined and dis...